Details:

Alternative Title:
MMWR. Morbidity and mortality weekly report
Corporate Authors:
United States. Advisory Committee on Immunization Practices.
Description:
In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other quadrivalent meningococcal conjugate vaccine, MenACWY-D(Menactra, Sanofi Pasteur), is licensed in the United States for prevention of meningococcal disease caused by serogroups A, C, Y, and W-135 among persons aged 2 through 55 years; MenACWY-D also is licensed as a 2-dose series for children aged 9 through 23 months. The Advisory Committee on Immunization Practices (ACIP) recommends that persons aged 2 through 55 years at increased risk for meningococcal disease and all adolescents aged 11 through 18 years be immunized with meningococcal conjugate vaccine. ACIP further recommended, in January 2011, that all adolescents receive a booster dose of quadrivalent meningococcal conjugate vaccine at age 16 years. This report summarizes data supporting the extended age indication for MenACWY-CRM and the interchangeability of the two licensed meningococcal conjugate vaccines.
Subject:
[+]
Adolescent
Adult
Age Factors
Child
Child, Preschool
Humans
Immunization, Secondary
Immunization Schedule
Licensure
Meningococcal Infections
Meningococcal Vaccines
Middle Aged
Practice Guidelines As Topic
Risk

Source:
MMWR. Morbidity and mortality weekly report. 2011; 60(30):1018-9.
Pubmed ID:
21814165
Document Type:
Journal Article
Collection(s):
Advisory Committee on Immunization Practices (ACIP)
Guidelines and Recommendations
Main Document Checksum:
[+]
urn:sha256:50fae7efc399fc12d22aa6a99fdd661346cf0010192615aad18035be4c0cc729
File Type:

Supporting Files

• No Additional Files

More +